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Results: Thirty-	one	participants	 (eleven	 informal	 carers,	 four	 people	with	dementia	
and	sixteen	HSCPs)	were	interviewed.	Three	key	themes	were	identified:	the	key	chal-
lenges,	 improving	medication	management	 and	 the	 role	of	 pharmacists.	 The	 caring	
role	 commonly	 included	 responsibility	 for	 medication	 management	 which	 created	
both	practical	problems	and	an	emotional	burden.	This	burden	was	worsened	by	any	
difficulty	in	obtaining	support	and	if	the	person	with	dementia	was	on	a	complex	regi-







K E Y W O R D S
community	pharmacists,	dementia,	informal	carers,	medication	management
1  | INTRODUCTION





pharmacy	 input,	 drug	 interactions,	 comorbidity	 and	 polypharmacy,	
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amongst	 others.3–6	 The	 cognitive	 impairment	 characteristic	 of	 de-
mentia	 may	 result	 in	 a	 lack	 of	 capacity	 to	 safely	 self-	administer	
medication.7,8	 Despite	 people	 with	 dementia	 being	 particularly	
susceptible	 to	 adverse	drug	events,	 they	 are	 commonly	prescribed	
complex	medication	 regimes	 and	 on	 average	 receive	 five	 different	
medicines.7,9
Medication	 management	 “is	 the	 entire	way	 that	 medicines	 are	
selected,	procured,	delivered,	prescribed,	administered	and	reviewed	
to	optimize	 the	 contribution	 that	medicines	make	 to	 producing	 in-
formed	 and	 desired	 outcomes	 of	 patient	 care”.10	 With	 increasing	
cognitive	 impairment,	 the	 core	 symptom	 of	 dementia,	 medication	
management	is	often	shifted	from	the	personal	responsibility	of	the	
person	with	dementia	to	the	control	of	formal	(paid)	or	informal	(fam-




to	 administer	 medication.16,17	 Previous	 research	 has	 identified	 the	
role	of	informal	carers	as	advocates	and	their	potential	contribution	

















on	 the	 supply	 of	medicines	 to	 providing	 clinical	 services.27,28 These 





are	poorly	developed	and	 the	need	 for	 further	 research	on	ways	 to	












An	 exploratory	 qualitative	 study	 design	 that	 followed	Consolidated	
Criteria	 for	Reporting	Qualitative	studies	 (COREQ)	guidelines35 was 
employed	(see	appendix	for	further	details).	A	focus	group	conducted	





























•	 They	 had	 provided	 or	 still	 provide	 some	 sort	 of	 assistance	with	
medication	management	to	a	person	who	has	been	diagnosed	with	
dementia	and	is	living	in	the	community;
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2.5 | Data analysis
A	qualitative	framework	analysis	was	undertaken	in	order	to	explore	





The	 transcripts	 were	 transcribed	 verbatim.	 TM	 and	 IM	 inde-
pendently	 reviewed	 the	 transcripts.	Disagreements	on	 the	 interpre-
tation	and	analysis	of	the	data	were	then	discussed	between	TM	and	















in	 people	 with	 dementia	 (empowerment	 and	 communication	 from	
health	professionals)	and	the	role	of	pharmacists.
3.1 | Key challenges experienced by informal 
carers and people with dementia: the caring role, the 








So in your opinion, does managing your medication affect 
your daily life 
(question from research associate)?
Not really, no, not really. I’ve got it sussed out. 
(Informal carer; pp3).
No, not really, no. It’s all right if I do it in advance (discuss-
ing organising the medication), you see, I know what to do, 
so… It’s really three times a day I have to remember. But 
then it’s usually when we’re eating, so it’s part of the ritual 




Before this sort of thing came out which I didn’t know 
about, they came in a small bottle and, obviously, you 
have to take certain ones at certain times. Well, I used 
to get into a right two and eight (Cockney rhyming slang 
for a state). And it…well, it just was a muddle. And then 
(community pharmacy chain), I used to go to (community 
pharmacy chain), and then they started putting them into 
packs like this. 
(Informal carer; pp2).
However,	 there	 is	 still	 frequently	 an	 emotional	 burden	 associated	
with	 medication	 management	 and	 carers	 expressed	 an	 obligation	 to	
being	responsible	for	managing	the	medication	of	the	person	they	are	
looking	 after;	 this	 included	 prioritizing	 the	 health	 of	 the	 person	 they	
cared	for	over	their	own	health:
Sometimes I feel fed up but what can I do? That is my 
duty…I forget my medicine but I never forget his 
(Informal carer; pp27).
On	further	exploration,	informal	carers	linked	this	burden	to	the	fact	
that	 the	medication	was	 not	 improving	 the	 behaviours	 and	 cognitive	
problems	characteristic	of	dementia:
I was frustrated with myself. Why? With the medicine and 
she was getting worse and worse…the way she was behav-
ing that I was worried about. 






I wouldn’t know which ones to take, there’s too many of 
them. 
(Person with dementia; pp1).
I have missed (doses of medication) occasionally. 
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So all these [health issues] require medication…It’s keeping 




Make sure that you got enough tablets to last 
(Informal carer; pp3).
I think the main problem with the medication was having 
to go and get it and remembering, “Oh, there’s only that 
many left of that particular one, I’d better order some 





to	 make	 decisions	 about	 administering	 medication	without	 sufficient	
support	from	HSCPs:
And now I discovered we’ve run out of brown (Warfarin) 
and they didn’t bother to give as a prescription for it and 
it was the weekend. And I was going to go to the doctor 
but what I did was I’ve got a pill cutter. (OK). I cut the 






This is what I feel I need to see Dr X, I really do. I feel 
that the tablets that she’s on, they are not doing any-
thing. I often wonder, sort of, to experiment and not 
give her any tablets at all for a week and see what the 
outcome would be. But then it might be dangerous. It 
could be you know, she could just fall off the planet. 
This is why I want to speak to him. But it’s like trying to 




[Doctor said] Every three days, but I don’t give it to her 
every three days because it’s a morphine patch, it’s for 
pain. She isn’t saying that she’s…any pain. Following the 
prescription she’d be taking 8 paracetamol a day which I 
think is far too much to be honest with you. 
(Informal carer – pp16).
3.2 | Improving medication management in people 




support	 with	 medication	 management.	 Medication	 management	 is	
frequently	solely	dependent	on	informal	carers,	and	therefore,	target-
ing	them	is	the	best	way	to	improve	the	process:
I find organising things in the short term, I find it difficult 
(Person with dementia; pp1).
So that’s where the help needs to be improved, em-
powering carers…You can’t empower the patients be-
cause they’re already losing them (to the symptoms of 
dementia). 
(GP; pp5).
Yet,	 informal	 carers	may	 have	 their	 own	 health	 problems	 and	
therefore	 have	 to	 manage	 the	 medication	 of	 two	 people:	 them-
selves	 and	 the	person	 they	 care	 for.	The	majority	of	 the	 informal	
carers	agreed	that	having	to	manage	both	regimens	can	be	difficult	
as there is:
A lot to think about. Yes. That’s why I like to think about 
and with (the person with dementia cared for) not being 
on the ball, sort of business…I have to think about as 
well. 
(Informal carer - pp3).
HSCPs	need	 to	provide	 clear	 explanations	 so	 that	 informal	 carers	
fully	understand	the	treatments	 in	order	to	decrease	the	risk	of	medi-
cation	errors:
If they’ve sat there in a consultation and me or anyone 
else…”Oh, they’ve completely got that” and then a few 
months later…although the drug is no longer on…their 
medical records, at home they’ve still got boxes of tablets 
and they’re still taking them and they shouldn’t be 
(GP; pp15)
Therefore,	HSCPs	should	supply:
A little bit more…explanation…and then it’s easier to take 




Listen to the concerns of the relatives 
(Informal carer; pp14)




Written instructions, pictures and making sure that their…








It’s crazy. You need a magnifying glass as well as your 




Well, if they’re having problems taking it at the right time 
then I would say social services because they’d need 
prompting to take it. If it was because they couldn’t open 
bottles or they were getting pills mixed up, because you, 
like, you might get several tablets that look the same. You 
know, so that would be the pharmacist because you need 
identification. If it was because, like with PRN medication, 
you would maybe need a nurse to help them identify when 
they needed certain drugs. 
(Nurse – pp12)
Some	informal	carers	agreed	with	this	idea	and	added	that	this	sup-
port	 needs	 to	 take	 into	 consideration	different	 cultural	 traditions	 and	
religions:
Whoever is looking after (the person with dementia) if 
they (clinicians) are not aware of these issues, cultural 
issues, religious issues and traditions…then it’s a big 
problem…you have to build the confidence according to 
their traditions or religion so it plays a major part in that 
situation if you’re not aware (of cultural and religious 
 aspects)…South Asian people (may) have little knowledge 
about English. 
(Informal carer; pp25)
In	 addition,	 medication	 reviews	 were	 viewed	 as	 having	 a	 poten-
tially	positive	impact,	but	clinicians	may	lack	the	time	to	conduct	them	
adequately:
In a 20 minute appointment and looking at their medica-
tion is just one part of that…most people will probably say, 
“No, no, its fine, I’m taking them”. But actually, you know, I 
don’t know how in depth we go, really. 
(Nurse; pp7).
Again,	it	is	important	that	HSCPs	coordinate	any	review	and	share	
relevant	 information	 between	 themselves	 to	 improve	 the	 support	
given	and	the	treatment.	Failing	to	do	this	may	lead	to	several	issues:
Although the information does come back to us through 
the GPs, it may not always be the type of information 
that we always want…that patient may not be as well 
 adherent…and not presenting it to the doctor. 
(Pharmacist; pp23)
According	 to	most	of	 the	HSCPs	 interviewed,	medication	 reviews	
have	 significant	 potential	 to	 improve	 medication	 management	 but	
should	be	conducted	in	the	patient’s	home	so	that	HSCPs	understand	
the	full	picture	of	the	whole	process:
That’s easier isn’t it when you are out there seeing them in 
their home. It’s very difficult when people come in because 
you have no idea really…like I say, things can sound very 
chaotic but actually when you are in there, you think, “Oh, 
no, it’s OK, it’s working”. It’s very difficult when you are not 






If you’ve got a choice of inhaler but have these twice a 
day…or there’s one that’s once a day you’d, hopefully, go 
for the one that’s once a day one if it carries the appro-
priate medication. So, it’s just simplifying everything…get 
them the best medication possible, make it simple and 
then they are going to use it. 
(Nurse; pp9)






Well, it’s got to be the doctors, hasn’t it, and nurses… 
they’re the ones, aren’t they (that provide support for med-
ication management)…rather than the pharmacists…they 
just provide it (medication), don’t they. 
(Informal carer; pp1)
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So how do you think pharmacists could improve support 
to people with dementia and their carers when it comes to 
managing the medication? 
(Question from research associate)
Yes, I mean they could give…they can sort the tablets out 





Well, I think we’re very lucky in this country in that we do 
have a community network of expert pharmacists who are 





The main thing is if the pharmacist is attached to the prac-
tice and to the patient that would be great…I mean, why 
haven’t they [doctors] got such good relationships with 




the	 support	 they	provide	 to	 people	with	 dementia	 and	 their	 informal	
carers:
Well, I think the community pharmacists are left out of 
the clinical loop, the loop of communication between GPs, 
specialist nurses and the hospital…they don’t realise the 
potential for the community pharmacist to be a referral, 
you know, to co- ordinate…If we had access to medical 





cist	with	 the	 knowledge	 to	 educate	 could	mean	 better	 support	 for	
medication	management	to	people	with	dementia	and	their	informal	
carers:
Somebody in pharmacies that oversees all dementia 
 patients…named contact for families that if they are con-







Pharmacist that could go and visit people at home. 
(GP; pp15)
People (who) are alone, or, like, the carer isn’t up to doing 





We do not have a commissioned service where we can do 
medicines use reviews at the patient’s home. However, my 
colleagues in the neighbouring (area)…do have it…and it’s 





person	with	dementia,	 informal	 carers	 and	various	HSCPs.	 Informal	
carers	have	a	pivotal	role,	but	yet	frequently	find	managing	the	medi-
cation	 of	 someone	 with	 dementia	 challenging.	 Indeed,	 even	 carers	
who	stated	that	they	had	everything	under	control	identified	a	‘duty	
to	cope’	and	associated	emotional	burden.	This	echoes	 the	findings	
elsewhere	where	 informal	 carers	 identified	 that	 any	 failure	 to	 cope	
would	be	viewed	as	their	fault.26,38,39	This	challenge	increased	as	the	
complexity	of	the	regimen	increases	and	if	the	carers	lacked	adequate	
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input.28,41	 Equally	 importantly,	 we	 found,	 like	 other	 research,	 that	 
informal	 carers	 tended	 to	 view	 the	 role	 of	 pharmacists	 in	 terms	 of	
medication	supply.5,26
Other	 studies	 have	 identified	 high	 levels	 of	 polypharmacy	 with	
potentially	inappropriate	prescribing	in	people	with	dementia	ranging	









More	 generally,	 medicine	 optimization	 –	 defined	 as	 a	 ‘person-	
centred	approach	to	safe	and	effective	medicines	use,	to	ensure	peo-
ple	 obtain	 the	 best	 possible	 outcomes	 from	 their	 medicines’	 –	 has	
been	identified	a	key	priority	within	primary	care.43,44 Further research 
on	how	to	 improve	outcomes	from	medication	and	deliver	medicine	
optimization	is	needed.44	Deprescribing	which	is	considered	to	be	‘the	






4.1 | Implications for clinicians and policymakers
Clinicians	 and	policymakers	 need	 to	be	 aware	of	 the	 challenges	 in-
volved	and	 that	even	 informal	 carers	who	do	not	 report	difficulties	
may	be	experiencing	an	emotional	burden.	Evidence-	based	guidelines	
need	to	consider	this	burden,	which	is	worsened	as	the	complexity	of	





cal	 records	 and	 be	 coordinated	with	 other	medication	 optimization	








































Community	 pharmacists	 could	 potentially	 develop	 an	 enhanced	
role	 in	supporting	medication	management	in	this	area.	The	support	
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APPENDIX 
Demographic Details of Participants 
Interview number Interviewee(s) Gender Location Ethnicity
001 Person	with	dementia	and	Informal	carer Male	(M)	and	Female	(F) West	Midlands White	(both)
002 Informal	carer M South	West	England White
003 Person	with	dementia	&	Informal	carer M	&	F West	Midlands White	(both)
004 Informal	carer F North	East	England White
005 General	practitioner	(GP) F North	East	England White
006 Informal	carer F North	East	England White
007 Practice	nurse F North	East	England White
008 GP M London White
009 Practice	nurse F West	Midlands White
010 Paid	carer F West	Midlands White
011 Person	with	dementia M West	Midlands White
012 District nurse F West	Midlands White
013 District nurse F West	Midlands White
014 Person	with	dementia	and	Informal	carer M	&	F West	Midlands White	(both)




017 Paid	carer F South	East	England White
018 District/mental health nurse F West	Midlands White
019 GP F West	Midlands White
020 Paid	carer F South	East	England White
021 Community	pharmacist F Yorkshire White
022 Community	pharmacist M Yorkshire White
023 Community	pharmacist M London South	Asian
024 Community	pharmacist F South	West	England Not	known
025 Informal	carer M Yorkshire South	Asian
026 Informal	carer F Yorkshire South	Asian
027 Informal	carer F Yorkshire South	Asian
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Semi- structured Interview Schedule
1.	Interview	schedule	for	informal	carers/people	with	dementia:	A	qualitative	study	exploring	medication	management	in	people	with	dementia	
living	in	the	community	and	the	potential	role	of	the	community	pharmacist
This semi- structured interview will consist of open- ended questions, which are split into four sections. However, these questions will depend upon how 
much detail the participant wants to give. Due to the sensitive nature of this topic, participants will take some direction over this interview and some 
questions may be missed out or expanded upon. Minor amendments may be made as the interview progresses as issues may arise that the researcher had 
not considered.
INTRODUCTION
Before we begin this interview, could you confirm whether you are caring for someone with dementia?
Thank you for taking part in this interview, I really do appreciate the time you have given. Before we begin, I want to make it clear that if you 
wish to skip any question(s) during the interview, or if you want to stop the interview, all you have to do is say; you do not need to give any 










In this next section, I am going to ask a few questions with regard to taking (if interviewing the person with dementia) or assisting somebody 
(if the carer) in taking medication. I want to remind you that these questions are to help us better our understanding of how people feel about 



































This semi- structured interview will consist of open- ended questions, which are split into three sections. However, these questions will depend upon how 
much detail the participant wants to give. Participants will take some direction over this interview and some questions may be missed out or expanded 
upon. Minor amendments may be made as the interview progresses as issues may arise that the researcher had not considered.
INTRODUCTION
Before we begin this interview, could you please confirm what your job title is?
Thank you for taking part in this interview, I really do appreciate the time you have given. Before we begin, I would like to make it clear that 
if you wish to skip any question(s) during the interview, or if you want to stop the interview, all you have to do is say; you do not need to give 
any explanation for doing so.
Are	you	happy	for	me	to	begin?
Can	you	tell	me	what	your	current	role	is	in	regard	to	caring	for	people	with	dementia?
The next few questions are going to be about your experience of reviewing and assisting medication management for dementia patients and 











The last section of the interview focuses on your opinions about current practice.
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DOMAIN 2:  STUDY DESIGN
9. What methodological orientation was stated to underpin the 
study?
An exploratory, qualitative study was conducted employing semi-struc-
tured interviews. Data were analysed using framework analysis.
10. How were participants selected?
Informal carers were eligible if:
• They had provided or still provide some sort of assistance with medica-
tion management to a person who has been diagnosed with dementia 
and is living in the community;
• Do not receive any sort of payment (excluding carers’ allowance).
Health and social professionals were eligible if:
• they had been in contact with or had been providing assistance to peo-
ple with dementia
11. How were participants approached?
Participants were recruited from the Alzheimer’s society, Dementia UK, 
local surgeries and other professional networks, and local dementia sup-
port groups (including a support group for people with dementia in the 
black and minority ethnic [BME] community in Yorkshire). The institutions 
were contacted by LA and IM via telephone and email and asked about 
their willingness to collaborate in advertising the study. Also, they were 
provided with information and details of the research, what taking part in 
this study would involve and the criteria individuals had to meet to be able 
to participate.
Recruitment was also conducted through snowball effect as contacts 
were requested to suggest other PwD, informal carers and HSCPs who 
might be willing to take part in this study. After their approval to collabo-
rate in advertising this study, the contact details of IM and LA were pro-
vided and potential participants were free to contact IM and LA via email 
or phone to express their interest in participating. An email was then sent 
to all potential participants, who expressed an interest in the study, with 
an information sheet with details of the study and a consent form followed 
by a request of their availability in case they agreed in taking part.
12. How many participants were in the study?
The final sample comprised of 31 participants [eleven informal carers; 
four PwD, sixteen Health or Social Care Professionals (HSCPs). From the 
sixteen HSCPs, four were general practitioners, five were nurses (practice 
and district nurses), three were paid carers and four were community 
pharmacists].
13. How many people refused to participate or dropped out?
None.
14. Where was the data collected?
The interviews with carers and people with dementia were conducted in 
the person’s home. The interviews with health and social care professionals 
were conducted either face-to-face in their place of work or over the phone.
COREC GUIDELINES
DOMAIN 1:  RESEARCH TEAM AND REFLEXIVITY
1. Which author/s conducted the interview or the focus group?
The interviews were conducted by Lydia Aston, Tiago Moutela or Andrea Hilton. Ian Maidment provided supervision.
2. What were the researcher’s credentials?
IM and AH are both pharmacists experienced in dementia care. LA and TM are Health Psychologists in training with a Masters in Health Psychology 
(including a module in advanced qualitative methods).
3. What was their occupation at the time of the study?
LA and TM were RAs specifically employed on this project. IM was a Senior Lecturer in Clinical Pharmacy, Aston University. AH was a Senior Lecturer 
at Hull University and a practising Community Pharmacist.
4. Was the researcher male or female?
IM and TM are male; LA and AH female. (NB – IM, LA and AH would be classed as British White; TM as Portuguese).
5. What experience or training did the researcher have?
IM and AH are pharmacists experienced in dementia care. LA and TM have conducted numerous qualitative research projects as part of their Masters 
and working as RA’s at Aston University.
6. Was a relationship established prior to study commencement?
LA and TM did not know any of the participants prior to study commencement. AH personally knew one of the pharmacists (given the geographical 
location), full informed consent was gained. They introduced the topic before the interview started and formally introduced themselves; this included ex-
plaining their current role in the project.
7. What did the participants know about the researcher?
The participants knew that IM of Aston University was leading the research and it was funded by Pharmacy Research UK and that LA and TM were 
research assistants and that AH was an academic from Hull University.
8. What characteristics were reported about the interviewer/facilitator?
LA and TM reported that they were research assistants conducting interviews in this area with little clinical knowledge; AH reported that she was an 
academic from Hull University.
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15. Was anyone else present besides the participants and 
researchers?
No-one else was present except for interviews pp 025, 026 and 027 
when a translator/interpreter from the same community was present. The 
interpreter did not hold an official qualification however they were from 
the same background and spoke the same language as the participants. 
The interpreters had been involved in previous studies where they have 
translated and were identified by an academic from the same community. 
He was confident of the accuracy of the translation and the results were 
consistent with other findings.
16. What are the important characteristics of the sample?
Informal carers were eligible if: they had provided or still provide 
some sort of assistance with medication management to a person 
who has been diagnosed with dementia and is living in the commu-
nity and did not receive any sort of payment (excluding carers 
allowance).
Health and social professionals were eligible if they had been in contact 
with or had been providing assistance to people with dementia.
17. Were questions, prompts, guides provided by the authors? Was it 
pilot tested?
The interview schedule consisted of open-ended questions to avoid 
leading participants’ responses. Prompts were included in the schedule 
and were employed if required. LA and IM with support from AH devel-
oped the interview schedule. No pilot test took place.
18. Were repeat interviews carried out?
No interviews were repeated.
19. Did the research use audio or visual recording to collect the data?
A Dictaphone was used to record the interviews. Data were transcribed 
verbatim.
20. Were field notes made during and/or after the interview or focus 
group?
Additional notes were made during the interviews.
21. What was the duration of the interviews or focus group?
The length of each interview was not formally recorded. However, on 
discussion with LA, TM and AH, the interviews with HSCPs lasted on aver-
age approximately 20 to 30 minutes; the interviews with carers/PwD 60 
to 90 minutes.
22. Was data saturation discussed?
Data saturation was reached and discussed amongst all co-authors.
23. Were transcripts returned to participants for comment and/or 
correction?
Transcripts were not returned to the participants, but potential themes 
were discussed between all co-authors.
DOMAIN	3: 	ANALYSIS	AND	FINDINGS
24. How many data coders coded the data?
TM and IM independently reviewed the transcripts. Disagreements on 
the interpretation and analysis of the data were then discussed between 
TM and IM until consensus was achieved. A systematic cross-comparison 
analysis was undertaken by TM, and reviewed by IM to identify the simi-
larities and differences between the different participants and to develop 
a set of themes which represent the whole corpus of data. TM and IM then 
discussed and agreed the final structure of the matrix for the analysis.
25. Did authors provide a description of the coding tree?
No.
26. Were themes identified in advance or derived from the data?
Themes were derived from the data. Three key concepts were elicited 
from the data with subthemes within these three themes.
27. What software, if applicable, was used to manage the data?
NVIVO software was used to manage the data.
28. Did participants provide feedback on the findings?
Participants did not provide feedback.
29. Were participant quotations presented to illustrate the themes/
findings? Was each quotation identified?
Extracts presented in the results section were drawn directly from the 
transcripts, which are recordings of the interviews.
30. Was there consistency between the data presented and the 
findings?
Yes there was consistency between the data presented and the findings.
31. Were major themes clearly presented in the findings?
Three key concepts were elicited from the data with subthemes within 
these three themes, and all three themes were discussed in the results 
section.
32. Is there a description of diverse cases or discussion of minor 
themes?
Yes, diverse cases have been discussed and the differences between the 
interview data from the carers and HSCPs. When relevant, minor themes 
were discussed.
